{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:49:21Z","timestamp":1790858961480,"version":"4.1.0"},"reference-count":50,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:p>The proper development and function of T cells is imperative in the creation of adequate cell-mediated and humoral immunity. Healthy term newborns have baseline immune immaturity, increasing their risk of infections, but significant immunologic consequences can occur, because of abnormal T-cell maturation. Combined immunodeficiencies can result, because B cells and natural killer cells rely on successful interactions with T cells to ensure their proper performance and survival. Severe combined immunodeficiency (SCID) is the most noteworthy of these conditions, leading to considerable early morbidity and often death by the age of 1 year if left untreated. Newborn screening for SCID is effective and allows for early implementation of lifesaving supportive measures, including protective isolation, initiation of prophylactic antimicrobials, caution with blood product transfusions, and avoidance of live vaccinations. Once a definitive diagnosis of SCID has been established, treatment frequently involves bone marrow or stem cell transplantation; however, enzyme replacement and gene therapy are also becoming options in those with SCID due to adenosine deaminase deficiency and other forms of SCID. Neonatal clinicians should understand the screening and diagnostic approach to SCID along with the initial management approaches for these extremely high-risk patients.<\/jats:p>","DOI":"10.1542\/neo.20-6-e326","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T13:25:23Z","timestamp":1559309123000},"page":"e326-e335","source":"Crossref","is-referenced-by-count":10,"title":["Severe Combined Immunodeficiency: A Review for Neonatal Clinicians"],"prefix":"10.1542","volume":"20","author":[{"given":"Thomas F.","family":"Michniacki","sequence":"first","affiliation":[{"name":"Pediatrics and Communicable Diseases, Division of Pediatric Hematology\/Oncology, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Seth","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Allergy, Asthma, & Immunology, Wayne State University, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Secord","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Allergy, Asthma, & Immunology, Wayne State University, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2019,6,1]]},"reference":[{"key":"2021121007352179500_B1","volume-title":"Nathan and Oski\u2019s Hematology and Oncology of Infancy and Childhood","author":"Orkin","year":"2015","edition":"8th ed."},{"issue":"5","key":"2021121007352179500_B2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cppeds.2005.11.001","article-title":"Newborn immunology: relevance to the clinician","volume":"36","author":"Lewis","year":"2006","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"issue":"1","key":"2021121007352179500_B3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.siny.2015.12.005","article-title":"Primary immunodeficiency in the neonate: Early diagnosis and management","volume":"21","author":"Walkovich","year":"2016","journal-title":"Semin Fetal Neonatal Med"},{"key":"2021121007352179500_B4","volume-title":"Cellular and Molecular Immunology","author":"Abbas","year":"2018","edition":"9th ed."},{"issue":"4","key":"2021121007352179500_B5","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.iac.2015.07.002","article-title":"Severe combined immunodeficiency disorders","volume":"35","author":"Chinn","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"issue":"7","key":"2021121007352179500_B6","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/jama.2014.9132","article-title":"Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States","volume":"312","author":"Kwan","year":"2014","journal-title":"JAMA"},{"issue":"2","key":"2021121007352179500_B7","doi-asserted-by":"crossref","first-page":"AB145","DOI":"10.1016\/j.jaci.2010.12.576","article-title":"Are severe combined immune deficiency cases missed at a Children\u2019s Hospital","volume":"127","author":"Poowuttikul","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2021121007352179500_B8","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jaci.2013.09.044","article-title":"Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience","volume":"133","author":"Shearer","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"2021121007352179500_B9","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1182\/blood.V98.6.1847","article-title":"Transplacentally acquired maternal T lymphocytes in severe combined immunodeficiency: a study of 121 patients","volume":"98","author":"M\u00fcller","year":"2001","journal-title":"Blood"},{"issue":"6","key":"2021121007352179500_B10","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jaci.2008.09.037","article-title":"Omenn syndrome: inflammation in leaky severe combined immunodeficiency","volume":"122","author":"Villa","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2021121007352179500_B11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10875-017-0465-8","article-title":"The 2017 IUIS phenotypic classification for primary immunodeficiencies","volume":"38","author":"Bousfiha","year":"2018","journal-title":"J Clin Immunol"},{"key":"2021121007352179500_B12","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-662-52909-6","volume-title":"Primary Immunodeficiency Diseases: Definition, Diagnosis, and Management","author":"Rezaei","year":"2017","edition":"2nd ed."},{"issue":"4","key":"2021121007352179500_B13","first-page":"281","article-title":"Principles and practice of mass screening for disease [in Spanish]","volume":"65","author":"Wilson","year":"1968","journal-title":"Bol Oficina Sanit Panam"},{"key":"2021121007352179500_B14","unstructured":"Immune Deficiency Foundation. IDF SCID newborn screening campaign. Available at: https:\/\/primaryimmune.org\/idf-advocacy-center\/idf-scid-newborn-screening-campaign. Accessed March 13, 2019"},{"issue":"9357","key":"2021121007352179500_B15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0140-6736(03)12513-5","article-title":"Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99","volume":"361","author":"Antoine","year":"2003","journal-title":"Lancet"},{"issue":"11","key":"2021121007352179500_B16","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1182\/blood-2010-08-300384","article-title":"Neonatal diagnosis of severe combined immunodeficiency leads to significantly improved survival outcome: the case for newborn screening","volume":"117","author":"Brown","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2021121007352179500_B17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10875-017-0373-y","article-title":"how we manage adenosine deaminase-deficient severe combined immune deficiency (ADA SCID)","volume":"37","author":"Kohn","year":"2017","journal-title":"J Clin Immunol"},{"issue":"3","key":"2021121007352179500_B18","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.semperi.2015.03.004","article-title":"History and current status of newborn screening for severe combined immunodeficiency","volume":"39","author":"Kwan","year":"2015","journal-title":"Semin Perinatol"},{"issue":"4","key":"2021121007352179500_B19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s10875-014-0029-0","article-title":"The case for mandatory newborn screening for severe combined immunodeficiency (SCID)","volume":"34","author":"Gaspar","year":"2014","journal-title":"J Clin Immunol"},{"issue":"2","key":"2021121007352179500_B20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaci.2004.10.012","article-title":"Development of population-based newborn screening for severe combined immunodeficiency","volume":"115","author":"Chan","year":"2005","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2021121007352179500_B21","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s10875-015-0152-6","article-title":"TREC based newborn screening for severe combined immunodeficiency disease: a systematic review","volume":"35","author":"van der Spek","year":"2015","journal-title":"J Clin Immunol"},{"key":"2021121007352179500_B22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/1479-5876-11-119","article-title":"Use of V(D)J recombination excision circles to identify T- and B-cell defects and to monitor the treatment in primary and acquired immunodeficiencies","volume":"11","author":"Serana","year":"2013","journal-title":"J Transl Med"},{"key":"2021121007352179500_B23","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jpba.2014.03.047","article-title":"Mass spectrometry in clinical chemistry: the case of newborn screening","volume":"101","author":"la Marca","year":"2014","journal-title":"J Pharm Biomed Anal"},{"issue":"6","key":"2021121007352179500_B24","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.jaci.2012.08.054","article-title":"Tandem mass spectrometry, but not T-cell receptor excision circle analysis, identifies newborns with late-onset adenosine deaminase deficiency","volume":"131","author":"la Marca","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"2021121007352179500_B25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jpba.2013.08.044","article-title":"The inclusion of ADA-SCID in expanded newborn screening by tandem mass spectrometry","volume":"88","author":"la Marca","year":"2014","journal-title":"J Pharm Biomed Anal"},{"issue":"6","key":"2021121007352179500_B26","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.jaci.2011.03.040","article-title":"Neonatal screening for severe combined immunodeficiency caused by an adenosine deaminase defect: a reliable and inexpensive method using tandem mass spectrometry","volume":"127","author":"Azzari","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"2021121007352179500_B27","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/17474086.2016.1180243","article-title":"Newborn screening for SCID: lessons learned","volume":"9","author":"Buelow","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"2021121007352179500_B28","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/ACI.0000000000000221","article-title":"Newborn screening for severe combined immune deficiency (technical and political aspects)","volume":"15","author":"Kobrynski","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"4","key":"2021121007352179500_B29","doi-asserted-by":"crossref","first-page":"e1298","DOI":"10.1542\/peds.2012-1921","article-title":"Challenges of newborn severe combined immunodeficiency screening among premature infants","volume":"131","author":"Ward","year":"2013","journal-title":"Pediatrics"},{"issue":"12","key":"2021121007352179500_B30","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1586\/1744666X.2014.980816","article-title":"Newborn screening for SCID: where are we now?","volume":"10","author":"Buelow","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"2021121007352179500_B31","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jaip.2015.06.007","article-title":"Newborn screening for severe combined immunodeficiency: changing the landscape of pediatric primary immunodeficiencies","volume":"3","author":"Nickels","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"2021121007352179500_B32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jpeds.2014.08.068","article-title":"Absence of the thymic shadow in a neonate suspected of primary immunodeficiency: not a straightforward clinical sign of immunodeficiency","volume":"166","author":"Nickels","year":"2015","journal-title":"J Pediatr"},{"issue":"10","key":"2021121007352179500_B33","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/ciu646","article-title":"Prevention of infections during primary immunodeficiency","volume":"59","author":"Aguilar","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2021121007352179500_B34","first-page":"249","article-title":"Prevention of infection in children and adolescents with primary immunodeficiency disorders","volume":"30","author":"Papadopoulou-Alataki","year":"2012","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"23","key":"2021121007352179500_B35","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1182\/blood-2013-02-380105","article-title":"How I treat severe combined immunodeficiency","volume":"122","author":"Gaspar","year":"2013","journal-title":"Blood"},{"issue":"25","key":"2021121007352179500_B36","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1182\/blood-2017-05-781849","article-title":"Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study","volume":"130","author":"Heimall","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2021121007352179500_B37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.clim.2005.07.006","article-title":"Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID)","volume":"117","author":"Chan","year":"2005","journal-title":"Clin Immunol"},{"issue":"1","key":"2021121007352179500_B38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2016-01-688226","article-title":"Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"128","author":"Cicalese","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2021121007352179500_B39","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J Clin Invest"},{"issue":"2","key":"2021121007352179500_B40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/humc.2016.29010.ind","article-title":"Investor Outlook: Rising from the ashes; GSK\u2019s European approval of Strimvelis for ADA-SCID","volume":"27","author":"Schimmer","year":"2016","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"6","key":"2021121007352179500_B41","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/mt.2016.98","article-title":"ADA-SCID gene therapy endorsed by European Medicines Agency for marketing authorization","volume":"24","author":"Yl\u00e4-Herttuala","year":"2016","journal-title":"Mol Ther"},{"issue":"335","key":"2021121007352179500_B42","doi-asserted-by":"crossref","first-page":"335ra57","DOI":"10.1126\/scitranslmed.aad8856","article-title":"Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency","volume":"8","author":"De Ravin","year":"2016","journal-title":"Sci Transl Med"},{"issue":"5","key":"2021121007352179500_B43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11882-016-0615-8","article-title":"Gene therapy for the treatment of primary immune deficiencies","volume":"16","author":"Kuo","year":"2016","journal-title":"Curr Allergy Asthma Rep"},{"issue":"2","key":"2021121007352179500_B44","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1089\/hum.2015.137","article-title":"Gene therapy for X-Linked Severe Combined Immunodeficiency: where do we stand?","volume":"27","author":"Cavazzana","year":"2016","journal-title":"Hum Gene Ther"},{"key":"2021121007352179500_B45","unstructured":"Autologous gene therapy for artemis-deficient SCID. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03538899. Accessed March 13, 2019"},{"key":"2021121007352179500_B46","unstructured":"Gene transfer for X-linked severe combined immunodeficiency in newly diagnosed infants. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01512888. Accessed March 13, 2019"},{"key":"2021121007352179500_B47","unstructured":"Phase I\/II trial of lentiviral gene transfer for SCID-X1 with low dose targeted busulfan conditioning. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03311503. Accessed March 13, 2019"},{"key":"2021121007352179500_B48","unstructured":"Gene transfer therapy for severe combined immunodeficieny disease (SCID) due to adenosine deaminase (ADA) deficiency. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00018018. Accessed March 13, 2019"},{"issue":"2","key":"2021121007352179500_B49","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.clim.2010.02.007","article-title":"Thymus transplantation","volume":"135","author":"Markert","year":"2010","journal-title":"Clin Immunol"},{"issue":"13","key":"2021121007352179500_B50","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood-2010-03-275966","article-title":"Multicenter survey on the outcome of transplantation of hematopoietic cells in patients with the complete form of DiGeorge anomaly","volume":"116","author":"Janda","year":"2010","journal-title":"Blood"}],"container-title":["NeoReviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/neoreviews\/article-pdf\/20\/6\/e326\/821610\/neoreviews_201800043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/neoreviews\/article-pdf\/20\/6\/e326\/821610\/neoreviews_201800043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T19:01:06Z","timestamp":1639162866000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/neoreviews\/article\/20\/6\/e326\/92085\/Severe-Combined-Immunodeficiency-A-Review-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6,1]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/neo.20-6-e326","relation":{},"ISSN":["1526-9906"],"issn-type":[{"value":"1526-9906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,1]]}}}